-+ 0.00%
-+ 0.00%
-+ 0.00%

Swiss Market Index Starts Week Upbeat; Roche Shares in Green

MT Newswires·11/16/2026 11:59:31
Listen to the news
11:59 AM EST, 11/16/2026 (MT Newswires) -- The blue-chip Swiss Market Index welcomed the new trading week on a positive note, closing Monday's trading session 0.57% higher, as investors assessed the latest economic releases and company updates. Switzerland's seasonally and sport event-adjusted gross domestic product expanded by 0.2% in the third quarter, supported by growth in the industrial sector while the services sector stagnated, according to provisional data from the State Secretariat for Economic Affairs. In the second quarter, GDP adjusted for sporting events grew 1.5%. Meanwhile, flash data from the Federal Statistical Office showed that the country's hotel sector saw a 2% annual increase in overnight stays for October. Hotel bookings by Swiss nationals were up 1.6%, while those from foreigners rose 2.3%. On the corporate front, Roche (RO.SW) secured approval from the US Food and Drug Administration for its Gazyva/Gazyvaro to treat primary membranous nephropathy, a chronic autoimmune disease that can progress to kidney failure, in adult patients who are at risk of disease progression. The regulator's positive decision marks its third approval of the drug in immune-mediated kidney diseases. The Swiss pharmaceutical major's stock gained 0.53% at closing. "[Primary membranous nephropathy] can lead to debilitating physical and psychological symptoms that place a heavy burden on patients, families and healthcare systems alike. This first-ever FDA approval delivers an important targeted treatment option for the pMN community and expands how many people may benefit from Gazyva/Gazyvaro across multiple severe immune-mediated kidney diseases," said Teresa Graham, chief executive officer of Roche's Pharmaceuticals division. Sandoz Group (SDZ.SW) rolled out Enzeevu in the US as a 2-milligram pre-filled syringe for the treatment of patients with various retinal diseases. Alongside the US launch for the Eylea biosimilar, the Swiss drugmaker signed an agreement to manufacture Enzeevu for private-label commercialization under a multi-year deal starting in mid-2027. Sandoz shares were flat on Monday's close.